Name: ML 239
Price: 276.00 USD

- Overview
  - Please contact us at for specific academic pricing.
    
    Background
    
    ML239 is the best-in-class inhibitor of the breast cancer stem cells with an IC50 = 1.16 µM. [1]
    ML239 was a selective inhibitor an IC50= 1.18 µM against HMLE_sh_ECad, demonstrated a >23-fold selectivity over the control line, and was toxic to another CSC-like line, HMLE_shTwist, and a breast carcinoma cell line, MDA-MB-231. Five genes (ATP6V0C, PKM2, PPDPF, RPL23, and SERINC2) were differentially regulated in HMLE_sh_GFP after treatment with ML239. Gene expression studies conducted with ML239-treated cells showed altered gene expression in the NF-κB pathway in the HMLE_sh_ECad line but not in the isogenic control line. ML239 was selectively toxic toward another CSC-like cell line, HMLE_Twist, and the breast cancer line, MDA-MB-231. Similar to the results observed in the HMLE_sh_ECad cell line, ML239 was potently toxic, inhibiting HMLE_Twist with an IC50 ~0.1 µM. ML239 displayed potent toxicity (IC50 = 2.81 µM) to the breast carcinoma cell line, MDA-MB-231 [1]. ML239 also alters the expression of genes in the NF-κB, MAPK and inflammatory cytokine pathways.
- Properties
  - Alternative Name
    
    (1Z,N'E)-N'-((1H-pyrrol-2-yl)methylene)-2-(2,4,6-trichlorophenoxy)acetohydrazonic acid
    
    CAS Number
    
    1378872-36-6
    
    Molecular Formula
    
    C13H10Cl3N3O2
    
    Molecular Weight
    
    346.60
    
    Appearance
    
    A crystalline solid
    
    Purity
    
    98.00%
    
    Solubility
    
    Soluble in DMSO
    
    Storage
    
    Store at -20°C
    
    * For Research Use Only

ML 239

ML 239

Background

We Also Recommend

CBR-5884

GSK180